Mutant IDH1 acts as a tumor suppressor when co-expressed together with TP53 and ATRX inactivating mutations in glioma, inducing genomic stability, DNA repair and resistance to genotoxic therapies.
Introduction
A recurrent mutation in Isocitrate Dehydrogenase 1 (IDH1 R132H ) is found in 80 % of lower grade gliomas (WHO grade II/III), and in a subset of high grade gliomas (WHO grade IV) (1, 2). Glioma patients whose tumors contain the mutation IDH1 R132H survive longer (1, 2) . Two main molecular subtypes of glioma, which harbor IDH1 R132H , have been identified: i) gliomas expressing IDH1 R132H , 1p/19q co-deletion, and TERT promoter mutations; and ii) gliomas expressing IDH1 R132H , mutant TP53, and inactivation of ATRX (2, 3) . In spite of a better long term prognosis 50-75% of IDH1 R132H containing gliomas undergo malignant transformation over time, becoming WHO grade IV glioblastomas (1, 4) .
The IDH1 mutation has been identified as an early event in glioma development, preceding mutations in TP53 and ATRX (5, 6) . IDH1 R132H persists after malignant transformation to WHO III/IV tumors and is present in recurrent gliomas (5, 6) . IDH1 R132H is a gain of function mutation that converts α-ketoglutarate to (R)-2-hydroxyglutarate (2HG) (7) (8) (9) . 2HG inhibits DNA and histone-demethylases, i.e. ten-eleven translocation enzymes (TETs) and lysine demethylases (KDMs) respectively, resulting in hypermethylation of DNA and histones (8, 9) . This elicits epigenetic reprogramming of the IDH1 R132H tumor cells' transcriptome (8) (9) (10) (11) . The mechanism of action of IDH1 R132H has not been elucidated. IDH1 R132H -dependent tumor sensitivity to chemo-and radiotherapy could explain the increased patient survival. Alternatively, IDH1 R132H could delay tumor progression through intrinsic biochemical activities (i.e., 2HG production, TETs and KDMs inhibition, epigenetic reprogramming, or NAD + -dependent processes) (7, 8, (10) (11) (12) .
Genomic instability is prevalent in gliomas; it is thought to promote tumorigenesis, and has been associated with aggressive behavior of tumor cells (13, 14) . DDR maintains genomic stability, and coordinates biological activities which include sensing DNA damage (DD), regulation of the mitotic cell cycle progression, and DNA repair mechanisms (15, 16) . ATM, a member of PI3K-like protein kinase family, plays a critical role in DDR (17) . ATM senses DD and activates DNA repair; it also regulates cell cycle arrest, required for efficient DNA repair (17) . ATM activation is critical to maintain genomic stability in response to DNA double strand breaks (DSB) (16) (17) .
Herein we demonstrate that IDH1 R132H in the context of ATRX and TP53 knock down (KD), increases DDR activity, resulting in enhanced genomic stability and increased MS in the genetically engineered mIDH1 mouse glioma model. Our data demonstrate that 2HG induces hypermethylation of histone 3 (H3) which has a strong epigenetic impact on the tumor cells' trancriptome. RNA-seq, Bru-seq, and ChIP-seq data from mIDH1 tumors uncovered enrichment of gene ontologies (GO) related to DDR, genomic stability, and activation of DNA repair pathways, especially upregulation of ATM signaling, homologous recombination (HR) DNA repair genes. As predicted by the molecular data, mIDH1 tumors exhibited enhanced DDR. Similar increases in DDR activity were observed in mIDH1 human glioma cells obtained from surgical specimens.
Consistent with the molecular data showing an increase in DDR, radiation failed to further increase survival in the mIDH1 tumor bearing animals. Pharmacological inhibition of DDR conferred radiosensitivity in mIDH1 tumor bearing mice, leading to prolonged MS. Our findings highlight that DDR inhibition could provide a novel therapeutic strategy for patients diagnosed with mIDH1 glioma in the context of ATRX and TP53 inactivation.
Results

Increased survival and inhibition of oligodendrocyte differentiation in a genetically engineered mIDH1 mouse glioma model
We generated a genetically engineered mouse model using the Sleeping Beauty transposase system (14, 18) to uncover the impact of IDH1 R132H , in the context of ATRX and TP53 inactivation, on tumorigenesis and cancer progression. Brain tumors were induced by RTK/RAS/PI3K pathway activation in combination with, shp53, shATRX and IDH1 R132H ( fig. S1A ). Mice from the three experimental groups, i.e., group 1: control (NRAS GV12-shp53); group 2: wt-IDH1 (NRAS GV12-shp53-shATRX) and group 3: mIDH1 (NRAS GV12-shp53-shATRX-IDH1 R132H ), developed brain tumors (fig. S1B) and had significant differences in MS (Fig. 1A) . The most aggressive tumor was wt-IDH1 (MS = 70 days) in agreement with previous results (14) . Notably, IDH1 R132H increased MS (163 days) ( Fig. 1A) . In all groups, tumor cells within the brain, did not co-express myosin VIIa We assessed 2HG levels in the mouse NS. In mIDH1 the 2HG concentration was on average 8.16 µg per mg of protein (µg/mg). We observed a reduction in 2HG production in mIDH1 NS from 8.16 µgr/mg to 2.21 µgr/mg (p < 0.0001) after treatment with AGI-5198, an IDH1 R132H inhibitor, which is equivalent to basal levels observed in wt-IDH1 NS. We next evaluated the effect of AGI-5198 on wt-IDH1 and mIDH1 NS' cell viability and proliferation. AGI-5198 inhibited cell viability ( fig. S2E ) and proliferation (2.8 fold; p < 0.0001) ( fig. S2F ) in mIDH1 NS in accordance with previous results in human glioma cells expressing IDH1 R132H (19) . Since previous reports showed that IDH1 R132H expression suppresses cellular differentiation (11, 19) , we evaluated the expression of oligodendrocyte and astrocyte differentiation markers. RNA-seq analysis of mIDH1 versus wt-IDH1 NS revealed a group of differentially expressed genes ( To confirm the impact of mIDH1 on cell differentiation, we performed immunofluorescence on wt-IDH1 and mIDH1 NS for OLIG2, GFAP and NESTIN as markers for oligodendrocytes, astrocytes and undifferentiated neuroprogenitor cells, respectively, in the presence or absence of AGI-5198. Treatment over 7 days of mIDH1 NS with AGI-5198 in combination with retinoic acid enhanced OLIG2 and GFAP expression ( fig. S4E ).
We also investigated the tumor initiation stem cell frequency using limiting dilution assay (LDA).
The LDA assay results indicate that both mouse NS and human glioma cells harboring mIDH1 have lower stem cell frequency when compare with wt-IDH1 glioma cells ( fig. S5 , A to J). In vivo analysis for tumor initiating cells (TIC) showed 100% of animals generated tumors and succumbed due to tumor burden after implantation of 30 x 10 5 , 10 x 10 5 , 3 x 10 3 and 1 x 10 3 wt-IDH1 cells; whereas with m-IDH1 only a 40% of animal generated tumors implanting 1 x 10 3 cells (fig. S5, K and L). These results indicate lower number of TIC in mIDH1 vs wt-IDH1 glioma cells.
In addition, we analyzed differences in the cell cycle profiles in our model. The percentage of actively proliferating cells was evaluated by EdU, and the mitotic index was evaluated by pH3(Ser10). Frequency of cells expressing EdU; pH3(ser10) or double positive (Edu + / pH3 + ) was higher in wt-IDH1 vs mIDH1 glioma cells in vivo (p < 0.0001) ( fig. S6 A to C).
IDH1 R132H induces H3 hypermethylation at genomic regions associated with DDR pathways
Mutant IDH1 tumors exhibited significantly increased levels of H3K4me3 (1.9 fold; p < 0.01), H3K27me3 (2.3 fold; p < 0.01) and H3K36me3 (7.1 fold; p < 0.01) ( Fig. 2A ). Similar expression of H3K4me1 ( Fig To assess the impact of H3 hypermethylation on epigenetic reprogramming in our model, we performed chromatin immunoprecipitation (ChIP) with deep sequencing (ChIP-seq), and evaluated differential enrichment of H3K4me3 and H3K27me3 peaks throughout the genome ( Fig. 2, B to H). High H3K4me3 and H3K27me3 occupancies were observed for genes in mIDH1 NS (Fig. 2 , B and C, and fig. S7G ). The heat maps show differential peaks of histone marks centered at the peak midpoint in mIDH1 NS (p < 1e-5 as the cutoff) ( Fig. 2 were around the transcription start sites (TSS) ( fig. S7H ). Identified peaks were then annotated to genomic features ( Fig. 2D ), comparing our data (histone mark peaks) to random regions (background). We observed increased levels of differential peaks for H3 marks in mIDH1 NS at promoters, 5' UTRs and around the first exon ( Fig. 2 , E to H). Since these regions are generally linked to transcriptional regulatory elements, our findings indicate that IDH1 R132H could participate in epigenetic reprogramming of gene expression. We addressed the biological significance of ChIP-seq results by functional enrichment analysis, identifying enriched GO terms linked to differential H3K4me3 and H3K27me3 peaks ( Fig. 2I ). Gene promoters enriched for H3K4me3 peaks are generally associated with transcriptional activation. Differential GO terms enriched in our model included DDR, cell cycle control, and regulation of cell development ( Fig. 2I ). On the other hand, gene promoters enriched in H3K27me3 histones are generally associated with transcription repression, and differential GO enrichment included terms related to cell differentiation. This would imply that IDH1 R132H prevents differentiation, which is in agreement with the RNA-seq and IHC results ( Fig. 1 , G to H, and figs. S4). Differential peaks for H3K4me3 around the promoter regions of BRCA1-associated ATM activator 1 (Brat1) and RAD51 associated protein 1 (Rad51ap1), which activate the HR DNA repair pathway were identified in mIDH1 NS.
These results suggest that DDR mechanisms are activated in mIDH1 gliomas (Fig. 2 , J and K).
IDH1 R132H upregulates expression ATM signaling pathway
We next compared the gene expression profiles of wt-IDH1 and mIDH1 tumor NS by RNA-seq analysis. We identified 1973 differentially expressed genes related to "DNA damage stimulus Fig. 3B and fig. S8B ). Fancd2, Rad50, and Rad51, involved in DNA repair and DDR were also upregulated in mIDH1 NS ( Fig. 1E and fig. S8A ).
WB analysis on tumor NS demonstrated that ATM, BRCA1, FANCD2, RAD50 and RAD51 were significantly elevated in mIDH1 NS (Fig. 3C ). In human glioma cells IDH1 R132H also increased expression of ATM and RAD51 ( Fig. 3 , D and E). IHC confirmed that RAD51, BRCA1, and ATM expression were enhanced in mIDH1 tumors, whereas p-DNA-PKcs protein expression, involved in non-homologous end-joining (NHEJ) repair, was not altered, and XCRCC4 is decreased ( fig.   S9A ). We validated these results by qPCR, observing significant increases in the mRNA levels of Atm (2.8 fold; p < 0.05), Brca1 (7.6 fold; p < 0.01), Fancd2 (3.1 fold; p < 0.01) and Rad51 (5.3 fold; p < 0.01) in mIDH1 NS ( Fig. 3F ). Finally, using ChIP-qPCR, we found that H3K4me3, but not H3K27me3, was significantly enriched in mIDH1 versus wt-IDH1 NS for both Atm (1.8 fold; p < 0.0001) ( Fig. 3G ) and Brca1 (2.2 fold; p < 0.0001) ( Fig. 3H ) genes at the proximal promoter regions, around TSS (primer sites Atm 2: -331/-451 and Brca1: -313/-413).
IDH1 R132H enhances DNA repair and DDR activity
Gene expression analysis suggested that IDH1 R132H could enhance HR DNA repair and DDR ( Fig.   4A ). Thus, we performed a functional DNA repair assay ( Fig. 4B ) in human glioma cells ( Fig. 4C) and mouse NS expressing wt-IDH1 or mIDH1 ( Fig. 4D ). Human and mouse mIDH1 glioma cells exhibited enhanced HR DNA repair efficiency versus wt-IDH1 cells (SJGBM2: 3.4 fold, p < 0.001; MGG8: 1.8 fold, p < 0.01; mouse NS: 1.6 fold; p < 0.01) ( Fig. 4 , C and D). In wt-IDH1 NS the addition of 2.5mM of (2R)-Octyl-α-hydroxyglutarate (O-2HG), a cell cell-permeable derivative of the D-isomer of 2HG, enhanced HR-repair efficiency (Fig. 4E ). These results demonstrate that IDH1 R132H through 2HG increases the efficiency in HR-repair.
We next quantified the kinetics of γH2AX and 53BP1 foci formation using immunofluorescence, in response to ionizing radiation (IR) (Fig. 4, F A similar trend was observed in 53BP1 foci formation, where the average foci number per cell was significantly increased 0.5-hour after IR in both wt and mIDH1 NS (p < 0.0001) ( Fig. 4G ).
However, mIDH1 NS reached basal levels before wt-IDH1 NS, indicating faster DSB-repair. In addition, we performed a neutral comet assay to assess genome integrity and DSB repair kinetics in response to IR ( fig. S9C ). IR immediately generated DNA-damage characterized by increased nuclear tail lengths, which is proportional to the number of DSBs at neutral pH. Scores were proportionately higher (longer tails) for wt-IDH1 versus mIDH1, indicating greater DNA-damage at early time points (p < 0.05) ( fig. S9C ). We next studied the phosphorylation status of H2AX (γH2AX), CHK2 (pCHK2), RPA32 (pRPA32) and ATM (pATM) after IR. WB data showed a peak of γH2AX 0.5 hours after IR exposure in wt-IDH1 and mIDH1 mouse NS ( Fig. 4H ). However, the γH2AX signal decreased in mIDH1 NS at 4 hours post-IR, compared to wt-IDH1 NS, indicating that mIDH1 NS repaired DNA more efficiently (Fig. 4H ). A similar trend was observed in mIDH1 NS for pCHK2, p-RPA32 and p-ATM, whose signal decreased after 4 hours; while in wt-IDH1 the signal remains positive at 48 hours post-IR ( Fig. 4H ). Consistent with the kinetic of DNA-repair enzymes phosphorylation after IR observed in mouse NS, human glioma cells expressing IDH1 R132H displayed a similar pattern ( Fig. 4I and S9D ). Our ChIP-seq and RNA-seq analysis underpin these results, i.e., IDH1 R132H expression correlates with enhanced DNA repair efficiency (Figs. 1E and 2I). This was also assessed by Bru-seq analysis ( Fig. 4J ), which enables the identification and quantification of nascent RNAs to establish differences in relation to transcription rates of genes. Bru-seq results show that mIDH1 NS display higher transcription rate for Atm and Rad50 (fold change > 1.5) compared to wt-IDH1 NS (Fig. 4 , K and L). Cell viability evaluated in response to IR was higher in mIDH1 NS compared to wt-IDH1 NS (~2-fold; p < 0.0001) ( Fig. 4M ). In addition, mIDH1 NS showed decreased NHEJ-repair activity ( fig. S9F ), which is an error-prone DNA-repair mechanism compared with HR-rapair (20) .
Since previous studies suggest that RAS pathway activation can confer radioresistance (21, 22) , we validated our results using NS generated from a mIDH1 glioma model independent of RAS activating mutations (23) . Brain tumors were induced with RCAS PDGFB, IDH1 (mutant or wild type), and shP53 in mixed background NTva, Ink4a/Arf -/mice (23) . We engineered the NS to encode shATRX in order to generate glioma cells with the following genetic alterations: PDGFB/shP53/shATRX/Ink4a/Arf -/-/mIDH1 or PDGFB/shP53/shATRX/Ink4a/Arf -/-/wt-IDH1. Using this model, we confirmed that mIDH1 confers radioresistance IR when compared to wt-IDH1 (~2 fold lower, p < 0.0001) ( Fig. 4N ). Likewise, human glioma cells harboring IDH1 R132H displayed higher viability versus wt-IDH1 glioma cells in response to IR (2.3 fold; p < 0.0001) ( Fig. 4O) .
These results were further validated in human glioma cells with endogenous expression of IDH1 R132H in the context of ATRX and TP53 inactivation (SF10602 and LC1035); which showed 
IDH1 R132H confers radioresistance in intracranial glioma models
To investigate the in vivo effects of mIDH1 in response to IR, we designed a pre-clinical trial using an intracranial glioma model ( Fig. 5A ). At 7 days post implantation (DPI) with wt-and mIDH1 NS, animals were treated with IR at the indicated doses. Untreated animals harboring wt-IDH1 tumors exhibited a MS of 21 days, which was significantly increased after 20 Gy (MS =51; p=0.0005) ( Fig. 5B ). In contrast, animals harboring mIDH1 tumors exhibited MS = 33 days, which did not increase in response to IR (MS = 38 DPI; p = 0.35) ( Fig. 5C ). These results demonstrate that IDH1 R132H confers radioresistance in vivo, likely through epigenetic reprogramming. To address this, we compared the genome wide gene expression profiles, using RNA-seq after IR ( Fig. 5 , D to I). We examined the following animal groups: i) IR wt-IDH1 tumors (wt-IDH1-R) versus nontreated (NT) wt-IDH1 tumors (wt-IDH1-NT) (Fig. 5D ), and ii) IR mIDH1 tumors (mIDH1-R) versus NT mIDH1 tumors (mIDH1-NT) ( Fig. 5E ). We found that the number of differentially expressed genes between mIDH1-R tumors and mIDH1-NT tumors is dose dependent and increased at 20
Gy compared to 10 Gy (Fig. 5F ). wt-IDH1 tumors exhibited lower numbers of differentially expressed genes compared to mIDH1 tumors at both 10 Gy and 20 Gy ( Fig. 5F ). Also, wt-IDH1-R tumors did not exhibit an increase of differentially expressed genes between 10 Gy and 20 Gy ( Fig. 5F ). This suggests that in vivo resistance to radiation-induced DD in mIDH1 glioma involves differential gene expression. Functionally, the upregulated genes in mIDH1 gliomas in response to IR are linked to regulation of cell proliferation, cell migration and cell homeostasis ( Fig. 5G ), functions that are also enriched (GO) in the enrichment map ( Fig. 5H ). In addition, several genes involved in DNA repair were upregulated in mIDH1-R ( (Fig. 5N ). However, in wt-IDH1 tumors γH2AX was elevated at 21 DPI versus 14 DPI (7.5 fold; p < 0.01), while in mIDH1, it decreased 4.5 fold (p < 0.05) at 21 DPI versus 14 DPI, implying better DNA repair activity ( Fig. 5N ). Taken together, these results suggest that IDH1 R132H induces radioresistance in vivo by altering gene expression, enhancing DDR and DNA repair mechanisms.
Inhibition of DDR pathways restores radiosensitivity in mIDH1 glioma
The increased DDR and radioresistance observed in mIDH1 glioma suggests that pharmacological DDR inhibition could improve the response to IR. In vitro cell viability assays show decreased sensitivity in mIDH1 NS after IR for both mouse glioma models (Fig. 6, A and B ). inhibition in response to IR, we utilized the intracranially mIDH1 model. The animals were treated with IR in combination with an ATM inhibitor (KU60019) (Fig. 6E ). Radiation or ATM inhibition alone did not modify MS compared to NT animals ( Fig. 6F ). However, KU60019 combined with IR significantly improved MS of mIDH1 mice (45 days) versus control (MS=30 days; p < 0.01) ( Fig. 6F ). This is consistent with decreased tumor size in mIDH1 animals treated with 20 Gy and KU60019 ( Fig. 6G ). To study the effect of cell cycle control in response to IR in mIDH1 glioma, we combined IR with CHK1/2 inhibition ( Fig. 6H ) in vivo. As with ATM inhibition, AZD7762 combined with IR significantly increased MS in mIDH1 glioma bearing mice ( Fig. 6I ). Tumor size was also significantly decreased after IR combined with AZD7762 at 14 DPI (5 fold; p < 0.0001) and 21 DPI (11 fold; p < 0.0001) ( Fig. 6J ). In wt-IDH1 tumors ATM inhibition using KU60019 in combination with IR does not improve MS compared to radiation alone treatment ( fig. S12J ).
However, CHK1/2 inhibition using AZD7762 combined with IR significantly increased MS in wtIDH1 glioma bearing mice (fig. S12K). We also assessed CC3 expression in mIDH1 tumors after treatment with IR combined with KU60019 or AZD7762 at 14 DPI (Fig. 6 , K and L). CC3 expression is increased in mIDH1 tumors after IR together with KU60019 or AZD7762, suggesting that DDR inhibition in combination with IR induces apoptosis. In mIDH1 human glioma cells, SF10602 and LC1035, AZD7762 was able to revert radioresistance ( Fig 
Discussion
Glioma patients whose tumors express IDH1 R132H exhibit longer MS (~ 6.6 years from diagnosis) compared with patients whose tumors express wt-IDH1 (~1.6 years from diagnosis)
(1, 2, 24). IDH1 R132H -mediated genomic stability may reduce mutational burden, leading to increased overall patient survival. In line with this, our mIDH1 mouse model exhibits increased median survival > 2-fold compared with wtIDH1 tumors. It was reported (3) that the glioma subgroup harboring IDH1 R132H , ATRX, and TP53 loss, also exhibits lengthening of telomeres. In our mouse glioma model telomere elongation is mediated by ALT (14, 25) . Genomic stability in our mIDH1 glioma model is mediated via increased DDR due to epigenetic reprogramming of the cancer cells' transcriptome ( Fig. 7) . DDR disruption is one of the hallmarks of gliomas, and other cancers (26, 27) . ATM kinase promptly senses DSB lesions on the DNA, setting in motion a signal transduction network, which activates appropriate responses that maintain genome integrity (28, 29) . Our Chip-seq data revealed enrichment of H3K4me3 marks at promoter/enhancer regions of genes involved in DDR and cell cycle progression. ChIP-qPCR results show an enrichment of the H3K4me3 mark at the proximal promoter region of Atm; which would elicit increased levels of Atm expression. Bru-seq and RNA-seq studies further confirmed transcriptional activation of Atm.
Upregulation of ATM was also found in LGG patients which harbor IDH1 R132H in combination with ATRX and P53 inactivation; this correlates with an increased survival in these patients (fig. S12, J, L and M; TCGA data-base, GlioVis plataform).
We discovered that IDH1 R132H induced transcriptional activation of Atm which results in efficient DD repair activity via HR (30) (31) (32) . Since the chromatin was less condensed in mIDH1 glioma cells, this could enable the recruitment of the DDR machinery to sites of DD. Thus, IDH1 R132H initiates a gene expression reprogramming cascade which enables glioma cells, also harboring ATRX KD and TP53 KD, to effectively respond to DD.
Mutations in IDH1/2 are also detected in 15% of AML patients, which correlates with unfavorable prognosis (33); intriguingly ATM expression is downregulated (through H3K9me3); also DDR functions and genomic stability are reduced (34) . AML-IDH1 mutant cells are more sensitive to chemotherapy, and highly malignant in their growth patterns. Thus, the production of 2HG leads to opposite effects in these two different cancers. This highlights the critical influence of the genetic context in which IDH1 R132H acts. Our mIDH1 glioma model expressed IDH1 R132H in the context of TP53 KD and ATRX KD, differing from AML, where ATRX inactivation is not present (33, 35, 36) .
We hypothesized that the increase in DDR elicited by mIDH1 could induce radioresistance, as mIDH1 glioma cells are able to repair the DD inflicted by IR more efficiently. It appears that IDH1 R132H induces genomic stability, which on one hand slows tumor growth; and on the other, it increases capacity to repair DSBs reducing the efficacy of radiotherapy. Previous studies used colon cancer cells, HeLa cells, and immortalized cells derived from high-grade gliomas, to suggest that IDH1 R132H suppresses HR-repair increasing radiosensitivity (37) (38) (39) (40) . None of these cells, however, originated from a patient derived IDH1 R132H glioma, none had defects in ATRX and p53, and no experiments were done orthotopically. These apparently opposing results, reinforce the notion that the effects of IDH1 R132H can vary according tumor type/subtype, and should be evaluated in an appropriate cellular and genetic context. Our results indicating that IDH1 R132H decreases radiosensitivity and enhances DDR in glioma were also validated in cells derived from glioma patients with endogenous expression of IDH1 R132H in the context of TP53 and ATRX inactivation. We also used a second mouse glioma model lacking RAS activating mutation (23) which encodes PDGFB, IDH1 R132H in combination with shP53; to which we added shATRX. In agreement with our results, a recent study using gliomaspheres demonstrated that that mIDH1 cultures are less sensitive to IR than wt-IDH1 cultures, however this work does not distinguish between co-deleted and non-co-deleted mIDH1 gliomas (41) .
Thus, we postulated that inhibiting DDR would restitute glioma radiosensitivity in the mIDH1 glioma sub-type under investigation. Indeed, when we blocked DDR by administrating ATM or CHK1/2 inhibitors, the tumors' sensitivity to IR therapy was restored ( Fig. 7) . In human patients, the effect of IDH1 R132H on IR response remains controversial. Evidence in favor of IDH1 R132H increasing or decreasing tumors' radiosensitivity has been published (24, (42) (43) (44) . As is evident in our mouse model, glioma patients expressing IDH1 R132H do live longer, but whether this is due to IDH1 R132H tumors growing slower, or whether they are more radiosensitive has not yet been conclusively demonstrated. Our data indicates that mice harboring tumors expressing IDH1 R132H live much longer than mice harboring wt-IDH1 tumors in the absence of any treatment. To conclusively demonstrate sensitivity to radiation in mIDH1 glioma patients, a control group not treated with radiation would be needed. Our in vivo analysis indicates that mIDH1 glioma bearing mice do not exhibit a therapeutic response to IR. Our data also demonstrates that the effects mediated by IDH1 R132H on DDR are dependent on the genetic context; i.e., additional genetic lesions present within the tumor cells (ATRX and TP53 KD). This is in agreement with the only study available in the literature which included 300 low-grade glioma patients (currently known to harbor IDH1 R132H ) treated with or without radiotherapy (44) . Similarly, survival of WHO II glioma patients expressing IDH1 R132H treated with TMZ, was not further improved by adding radiotherapy (42) . Also, a combination of Vincristine, Procarbazine, and CCNU for WHO II glioma leads to longer overall survival compared with patients receiving IR alone (43) . This would appear to suggest that tumors expressing IDH1 R132H remain sensitive to chemotherapy, but not radiotherapy.
In conclusion, we discovered the mechanism by which IDH1 R132H elicits epigenetic reprogramming of the ATM signaling pathway, which in turn increases DDR and genomic stability in the context of TP53 and ATRX inactivation. This correlated with extended MS of mice bearing mIDH1 tumors, and enhanced DNA repair in response to genotoxic insults (Fig. 7) . Our data proposes a novel therapeutic strategy combining radiation with DDR inhibitors to increase therapeutic efficacy in mIDH1 glioma patients. (B) Pathway enrichment map from differential gene expression of mIDH1 versus wt-IDH1 NS.
Figure legends
Clusters of nodes colored in red illustrate differential enrichment (upregulated) in mIDH1 NS (p < 0.05, overlap cutoff > 0.5) and they were extracted from the GSEA results comparing mIDH1 versus wt-IDH1 tumor NS (Fig. S4 ). The yellow highlighted circles indicate the nodes containing Atm whose upregulated GO terms are associated with DNA repair, DDR and chromosome stability. Each node is labeled with the specific GO term (Enrichment Map App from Cytoscape). were split into 6 groups: i) experimental group treated with 2 Gy/day for 5 days (total IR=10 Gy), euthanized at 14 DPI (n = 7); ii) no treatment group (NT), euthanized at 14 DPI (n = 5); iii) experimental group treated with 2 Gy/day for 10 days (total IR=20 Gy), euthanized at 21 DPI (n = 7); iv) no treatment group (NT), euthanized at 21 DPI (n = 5); v) experimental group treated with a 2 Gy/day for 10 days (total IR = 20 Gy), euthanized at moribund stage (n = 7); and, vi) non treatment group (NT), euthanized at moribund stage (n = 5). After euthanasia the tumors were processed for immunostaining and RNA-seq analysis. (E) Pre-clinical trial design for testing the impact of the ATM pathway inhibitor (KU60019) on the response to IR in a NS implanted tumor model. 7 days post NS implantation (DPI), the animals were separated into 8 treatment groups: i) untreated (NT) euthanatized at 14 DPI; ii) IR 2 Gy/ day for 5 days (total IR=10 Gy), euthanized at 14 DPI ; iii) KU60019 (continuous infusion for 5 days; total = 18 mg/Kg), euthanized at 14 DPI; iv) KU60019 (continuous infusion for 5 days; total = 18 mg/Kg) plus 2 Gy/ day for 5 days (total IR=10 Gy), euthanized at 14 DPI; v) untreated (NT), euthanized at moribund stage; vi) 2 Gy/day for 10 days (total IR = 20 Gy), euthanized at moribund stage; vii) KU60019 (continuous infusion for 10 days; total = 36 mg/Kg), euthanized at moribund stage; and viii) KU60019 (continuous infusion for 10 days; total = 36 mg/Kg) plus 2 Gy/ day for 10 days (total IR =20 Gy), euthanized at moribund stage. (J) Analysis of tumor size evaluated by tumor size quantification of mIDH1 brain tumors sections at 14 DPI with or without IR at the indicated doses, in the presence or absence of AZD7762.
Tumor growth is expressed as percentage relative to non-treated tumors at 14 DPI (100%).
(K) Analysis of CC3 expression evaluated by immunofluorescence staining performed on 50 µm vibratome mIDH1 brain tumor sections of at 14 DPI with or without IR treatment at the indicated doses, in the presence or absence of KU60019 (18 mg/ Kg) or AZD7762 (7.5 mg/ Kg). Scale bar 
